Recursion Pharmaceuticals, Inc. RXRX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligations.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s long-term debt?
- Recursion Pharmaceuticals, Inc. (RXRX) reported long-term debt of $7.18M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s long-term debt decreased by 56.3% year-over-year, from $16.45M to $7.18M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s long-term debt?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s long-term debt has grown at a -3.5% compound annual growth rate (CAGR), from $11.41M to $9.56M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.